Imagion Biosystems announces the presentation “MagSense® Imaging: Early Detection of Cancer Through Targeted Imaging.”
See the presentation “MagSense® Imaging“.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce